Volume 20, Issue 3, Pages (March 2004)

Slides:



Advertisements
Similar presentations
Volume 130, Issue 5, Pages (September 2007)
Advertisements

Crystal Structure of the Tandem Phosphatase Domains of RPTP LAR
Volume 9, Issue 2, Pages (February 2002)
Tsan Xiao, Par Towb, Steven A. Wasserman, Stephen R. Sprang  Cell 
Volume 27, Issue 4, Pages (October 2007)
Sebastian Meyer, Raimund Dutzler  Structure 
Volume 125, Issue 1, Pages (April 2006)
Structural Basis for Vertebrate Filamin Dimerization
The Structure of the Cytoplasmic Domain of the Chloride Channel ClC-Ka Reveals a Conserved Interaction Interface  Sandra Markovic, Raimund Dutzler  Structure 
Structural Basis for Dimerization in DNA Recognition by Gal4
Volume 26, Issue 3, Pages (March 2007)
Volume 25, Issue 4, Pages (October 2006)
Volume 23, Issue 11, Pages (November 2015)
Yvonne Groemping, Karine Lapouge, Stephen J. Smerdon, Katrin Rittinger 
The Interaction Properties of Costimulatory Molecules Revisited
Volume 18, Issue 8, Pages (August 2010)
Structure of the Angiopoietin-2 Receptor Binding Domain and Identification of Surfaces Involved in Tie2 Recognition  William A. Barton, Dorothea Tzvetkova,
Structure and T Cell Inhibition Properties of B7 Family Member, B7-H3
Volume 13, Issue 5, Pages (November 2000)
Crystal Structure of Tetrameric Arabidopsis MYC2 Reveals the Mechanism of Enhanced Interaction with DNA  Teng-fei Lian, Yong-ping Xu, Lan-fen Li, Xiao-Dong.
Volume 8, Issue 7, Pages (July 2000)
Structure and RNA Interactions of the N-Terminal RRM Domains of PTB
Volume 10, Issue 2, Pages (February 1999)
Phospho-Pon Binding-Mediated Fine-Tuning of Plk1 Activity
Crystal Structure of the MHC Class I Homolog MIC-A, a γδ T Cell Ligand
Solution and Crystal Structures of a Sugar Binding Site Mutant of Cyanovirin-N: No Evidence of Domain Swapping  Elena Matei, William Furey, Angela M.
Crystal Structure of the Human High-Affinity IgE Receptor
Volume 25, Issue 6, Pages (March 2007)
Volume 21, Issue 6, Pages (March 2006)
Volume 23, Issue 6, Pages (December 2005)
Structural Insights into the Inhibition of Wnt Signaling by Cancer Antigen 5T4/Wnt- Activated Inhibitory Factor 1  Yuguang Zhao, Tomas Malinauskas, Karl.
A Conformational Switch in the CRIB-PDZ Module of Par-6
Structure and function of mutationally generated monomers of dimeric phosphoribosylanthranilate isomerase from Thermotoga maritima  Ralf Thoma, Michael.
Crystal Structure of Recombinant Human Interleukin-22
Volume 124, Issue 5, Pages (March 2006)
Volume 18, Issue 8, Pages (August 2010)
Hongwei Wu, Mark W. Maciejewski, Sachiko Takebe, Stephen M. King 
Structural Basis for Vertebrate Filamin Dimerization
Zhenjian Cai, Nabil H. Chehab, Nikola P. Pavletich  Molecular Cell 
Volume 130, Issue 5, Pages (September 2007)
Volume 16, Issue 3, Pages (March 2008)
Daniel Olal, Oliver Daumke  Cell Reports 
Structural Basis of EZH2 Recognition by EED
Volume 7, Issue 4, Pages (April 2005)
Kevin M. Marks, Michael Rosinov, Garry P. Nolan  Chemistry & Biology 
Volume 91, Issue 5, Pages (November 1997)
Volume 16, Issue 8, Pages (August 2008)
Coiled-Coil Domains of SUN Proteins as Intrinsic Dynamic Regulators
Volume 8, Issue 5, Pages (November 2001)
Volume 12, Issue 7, Pages (July 2004)
Structural Basis for Specific Recognition of Reelin by Its Receptors
Microtubule Interaction Site of the Kinesin Motor
Structural Basis of Caspase-7 Inhibition by XIAP
Volume 11, Issue 2, Pages (February 2003)
Structural Basis for FGF Receptor Dimerization and Activation
Volume 15, Issue 6, Pages (December 2001)
Michael S. Kuhns, Mark M. Davis  Immunity 
Crystal Structure of the Human Myeloid Cell Activating Receptor TREM-1
Volume 30, Issue 5, Pages (June 2008)
Volume 91, Issue 5, Pages (November 1997)
Volume 110, Issue 9, Pages (May 2016)
Crystal Structure of a Polymeric Immunoglobulin Binding Fragment of the Human Polymeric Immunoglobulin Receptor  Agnes E. Hamburger, Anthony P. West,
Volume 11, Issue 1, Pages (January 2003)
Volume 18, Issue 5, Pages (May 2005)
Pingwei Li, Gerry McDermott, Roland K. Strong  Immunity 
Crystal Structure of the Extracellular Domain of a Human FcγRIII
Structure and Dimerization of a Soluble Form of B7-1
Volume 20, Issue 11, Pages (November 2012)
Volume 15, Issue 9, Pages (September 2007)
Structure of GABARAP in Two Conformations
Presentation transcript:

Volume 20, Issue 3, Pages 337-347 (March 2004) Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1  Xuewu Zhang, Jean-Claude D. Schwartz, Xiaoling Guo, Sumeena Bhatia, Erhu Cao, Lieping Chen, Zhong-Yin Zhang, Michael A. Edidin, Stanley G. Nathenson, Steven C. Almo  Immunity  Volume 20, Issue 3, Pages 337-347 (March 2004) DOI: 10.1016/S1074-7613(04)00051-2 Copyright © 2004 Cell Press Terms and Conditions

Figure 1 Monomeric State of Murine PD-1 (A) Elution profile of the purified extracellular Ig V-type domain of murine PD-1 from Superdex G75 Gel filtration chromatography. The single monodisperse peak at ∼17.5–18 min corresponds to a MW of ∼15 kDa. (B) Determination of the oligomerization state of the Ig V-type domain of murine PD-1 by sedimentation equilibrium. Filled points (closed circles) and open points (open circles) represent data collected at 25,000 rpm and 34,000 rpm, respectively. For clarity, every sixth point is plotted. Lines represent the best fit to a single-component sedimentation model yielding an estimate of the apparent MW, 13.3 kDa. The residuals of the corresponding points are randomly distributed, indicating that there is no oligomerization occurring and that the sample only consists of monomers. Immunity 2004 20, 337-347DOI: (10.1016/S1074-7613(04)00051-2) Copyright © 2004 Cell Press Terms and Conditions

Figure 2 Cellular Behavior of PD-1 (A) Images of CFP and YFP fluorescence on individual cells pre- and postbleaching. For clearer presentation, the color scheme of the images is reversed with CFP and YFP displayed in red and blue, respectively. (B) Distribution pattern of FRET efficiency (x-axis) as a function of number of cells (y-axis) for various groups as labeled. These data are pooled from four independent experiments, with total 14, 15, 21, and 25 cells examined for the tandem CFP-YFP, CTLA-4, L-PD-1, and S-PD-1, respectively. NC, negative control. (C) The correlation between the acceptor intensity (expressed as arbitrary units) and the FRET efficiency for individual regions of interest (ROI) is shown for the groups as marked. The total number of ROI analyzed for each group is 60 to 80. The line corresponds to the best linear fit and its slope is the measure of dependence of FRET efficiency on the concentration of acceptor molecules (expressed as acceptor intensity) (Kenworthy and Edidin, 1998). Immunity 2004 20, 337-347DOI: (10.1016/S1074-7613(04)00051-2) Copyright © 2004 Cell Press Terms and Conditions

Figure 3 Equilibrium Binding Affinity Measurement for Murine PD-1/B7-H1-Ig (A) Murine PD-1 over a series of concentrations (started from 78.0 μM and 1.4-fold dilution thereof) was injected over both the experimental flow cell (containing 3621 RUs immobilized murine B7-H1-Ig) and the reference flow cell. The final response at each concentration, represented by the continuous sensorgrams, was obtained by subtracting the response of the control cell from that of the experimental cell. (B) Nonlinear 1:1 Langmuir fitting and linear Scatchard plot (insert) of the binding data yield Kd of 4.17 ± 0.14 and 3.9 ± 0.07 μM, respectively. Immunity 2004 20, 337-347DOI: (10.1016/S1074-7613(04)00051-2) Copyright © 2004 Cell Press Terms and Conditions

Figure 4 Structure of Murine PD-1 (A) Ribbon diagram of the Ig V-type domain of murine PD-1. The front (green) and back (aqua) sheets are composed of A′GFCC′C″ and ABED strands, respectively. The CDR3 loop is labeled. The intrachain disulfide is shown in yellow. The four potential glycosylation sites are highlighted by showing the side chains of the Asn residues in red. (B) Hydrophobicity of the molecular surface of murine PD-1. Hydrophobic residues are colored in yellow, whereas hydrophilic residues are colored in red. The orientation of the molecule is similar to that in (A). The large hydrophobic patch on the front face (circled) was hypothesized to be the ligand-binding site. (C) Electrostatic molecular surface of murine PD-1. Negative and positive potentials are colored in red and blue, respectively. Charged residues surrounding the hydrophobic patch shown in (B) are labeled. The orientation of the molecule is similar to that in (A). Immunity 2004 20, 337-347DOI: (10.1016/S1074-7613(04)00051-2) Copyright © 2004 Cell Press Terms and Conditions

Figure 5 Comparison of Murine PD-1 and CTLA-4 (A and B) Two orthogonal views of a superimposition of murine PD-1 (green) and CTLA-4 (gray) structures. Parts with significant differences between the two structures are labeled. (C) Structure-based sequence alignment of PD-1 and CTLA-4. Identical residues between murine and human PD-1 are colored in yellow, whereas invariant residues between PD-1 and CTLA-4 are colored in red. Residues in murine PD-1 selected for mutation are highlighted with closed squares in blue. Residues in CTLA-4 involved in homodimerization and B7 binding (the MYPPPY loop) are highlighted with closed circles and closed squares, respectively. Cys122 mediating the interchain disulfide in CTLA-4 is highlighted with closed circles in green; a Glu residue occupies the equivalent position in PD-1. Immunity 2004 20, 337-347DOI: (10.1016/S1074-7613(04)00051-2) Copyright © 2004 Cell Press Terms and Conditions

Figure 6 Ligand-Binding Activities of the Murine PD-1 Mutants The wild-type and mutants of HA-tagged murine PD-1 at 1.7 μM were injected at 20 μl/min for 2 min over CM5 sensor chips coupled with murine B7-H1-Ig fusion protein. The final response of each protein was calculated by subtracting the response of the control cell from that of the experimental cell. The response levels of the mutants were compared with that of the wild-type protein to obtain the relative ligand-binding activities of the mutants. Immunity 2004 20, 337-347DOI: (10.1016/S1074-7613(04)00051-2) Copyright © 2004 Cell Press Terms and Conditions

Figure 7 Comparison of Ligand-Binding Surfaces of PD-1 and CTLA-4 (A) Molecular surface of murine PD-1. Residues whose mutations resulted in abolished or significantly reduced ligand binding are colored in red, whereas residues whose mutations had no significant effects on ligand binding or led to higher ligand binding are colored in gray. The ribbon diagram is shown on the right to indicate the orientation of the molecule. (B) Molecular surface of human CTLA-4 from the CTLA-4/B7-2 complex (Schwartz et al., 2001). Residues involved in ligand binding are colored in red. The ribbon diagram is shown on the right to indicate the orientation of the molecule. The CDR3 loops in both PD-1 (A) and CTLA-4 (B) are circled and labeled, showing the different contributions of this loop to ligand binding for these two receptors. Immunity 2004 20, 337-347DOI: (10.1016/S1074-7613(04)00051-2) Copyright © 2004 Cell Press Terms and Conditions